Xilio Therapeutics IncNASDAQ:XLONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8920
- TODAY'S CHANGE (%)-0.0280 (-3.0435%)
- Bid / Lots0.8700/ 1
- Ask / Lots0.9500/ 1
- Open / Previous Close0.9100 / 0.9200
- Day Range
- 52 Week Range
- Volume189,522
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XLO |
|---|---|---|
| 09:32 ET | 503 | 0.91 |
| 09:35 ET | 2500 | 0.9171 |
| 09:42 ET | 700 | 0.94 |
| 09:46 ET | 9650 | 0.92 |
| 09:48 ET | 11024 | 0.9 |
| 09:51 ET | 5435 | 0.89 |
| 09:53 ET | 4862 | 0.9005 |
| 09:55 ET | 5000 | 0.8701 |
| 09:57 ET | 100 | 0.889 |
| 10:00 ET | 700 | 0.889 |
| 10:06 ET | 500 | 0.885 |
| 10:08 ET | 2500 | 0.885001 |
| 10:11 ET | 3100 | 0.89 |
| 10:13 ET | 4995 | 0.89 |
| 10:15 ET | 2500 | 0.8777 |
| 10:22 ET | 100 | 0.88 |
| 10:26 ET | 261 | 0.88 |
| 10:27 ET | 2366 | 0.900499 |
| 10:29 ET | 7606 | 0.9181 |
| 10:42 ET | 7500 | 0.9006 |
| 10:45 ET | 7600 | 0.9005 |
| 10:47 ET | 2500 | 0.9074 |
| 10:49 ET | 20394 | 0.92 |
| 10:54 ET | 310 | 0.92008 |
| 10:58 ET | 100 | 0.9005 |
| 11:02 ET | 12246 | 0.8801 |
| 11:03 ET | 7500 | 0.8801 |
| 11:05 ET | 156 | 0.9 |
| 11:07 ET | 100 | 0.9 |
| 11:09 ET | 100 | 0.89 |
| 11:16 ET | 100 | 0.88 |
| 11:20 ET | 100 | 0.8802 |
| 11:27 ET | 7900 | 0.89 |
| 11:32 ET | 100 | 0.88 |
| 11:34 ET | 13249 | 0.9005 |
| 11:39 ET | 100 | 0.8832 |
| 11:45 ET | 2300 | 0.9005 |
| 11:52 ET | 800 | 0.88 |
| 12:12 ET | 900 | 0.894175 |
| 12:15 ET | 222 | 0.8803 |
| 12:32 ET | 4000 | 0.9 |
| 12:42 ET | 100 | 0.8895 |
| 12:50 ET | 100 | 0.8895 |
| 12:53 ET | 100 | 0.889 |
| 12:57 ET | 4000 | 0.896651 |
| 01:00 ET | 1000 | 0.896651 |
| 01:09 ET | 100 | 0.8814 |
| 01:13 ET | 100 | 0.8812 |
| 01:26 ET | 100 | 0.883 |
| 01:27 ET | 100 | 0.883 |
| 01:38 ET | 100 | 0.8832 |
| 01:47 ET | 100 | 0.8832 |
| 01:51 ET | 100 | 0.8832 |
| 02:12 ET | 200 | 0.895124 |
| 02:18 ET | 100 | 0.90912 |
| 02:23 ET | 100 | 0.8832 |
| 02:30 ET | 100 | 0.8837 |
| 02:59 ET | 100 | 0.89 |
| 03:03 ET | 100 | 0.909419 |
| 03:10 ET | 100 | 0.89 |
| 03:14 ET | 100 | 0.9 |
| 03:28 ET | 100 | 0.89 |
| 03:32 ET | 300 | 0.8901 |
| 03:33 ET | 15500 | 0.9012 |
| 03:39 ET | 1059 | 0.89 |
| 03:48 ET | 4833 | 0.92 |
| 03:50 ET | 200 | 0.92 |
| 03:55 ET | 261 | 0.90165 |
| 03:57 ET | 100 | 0.9022 |
| 04:00 ET | 1047 | 0.892 |
Nov 8, 2024
DJ Xilio Therapeutics Is Maintained at Outperform by Raymond James, from 1:33PM ET on Friday Nov 08, 2024 by Dow Jones
1:33PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors, from 9:15AM ET on Thursday Nov 07, 2024 by Dow Jones
9:15AM ET on Thursday Nov 07, 2024 by Dow JonesXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results, from 9:05AM ET on Thursday Nov 07, 2024 by Dow Jones
9:05AM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results, from 9:05AM ET on Thursday Nov 07, 2024 by Dow Jones
9:05AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 30, 2024
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, from 9:01AM ET on Wednesday Oct 30, 2024 by Dow Jones
9:01AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xilio Therapeutics Inc | 39.2M | -0.5x | --- |
OS Therapies Inc | 39.1M | -5.5x | --- |
Exicure Inc | 39.9M | -8.1x | --- |
AN2 Therapeutics Inc | 40.0M | -0.7x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 38.1M | -1.0x | --- |
Anebulo Pharmaceuticals Inc | 37.9M | -4.8x | --- |
Company Information
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Contact Information
- Headquarters
- 828 Winter Street, Suite 300WALTHAM, MA, United States 02451
- Phone
- 617-430-4680
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Clancy
- President, Chief Executive Officer, Director
- Rene Russo
- Chief Operating Officer
- Christopher Frankenfield
- Senior Vice President - Finance & Accounting
- Kevin Brennan
- Chief Medical Officer
- Katarina Luptakova
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $39.2M |
|---|---|
Revenue (TTM) | $4.6M |
Shares Outstanding | 44.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.72 |
Book Value | $1.33 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 8.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,408.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
